Fundraising FoxMass General Brigham Ventures — Full Portfolio
8 tracked investments · listed companies and verified rows first
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Founder)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSanofi VenturesREDMILE+9 more
CodaMetrix operates an AI-based contextual coding automation platform that converts clinical data and chargeable activities into billable, clinical, and demographic medical codes for hospitals and health systems.
AI & Machine LearningDigital HealthHealthtechBoston, US
Hamid Tabatabaie(Founder)inMark Pottle(Executive Officer)inJim Whelan(Mr. Whelan is the Chief Revenue Officer of the Issuer.)inKevin Schmitt(Mr. Schmitt is the Chief Engineering Officer of the Issuer.)inJay Aslam(Founder)Tara Bradley(Executive Officer)
Board seatRoger Kitterman· per SEC Form D · $15M raise · filed May 2025
Co-investorsCU Healthcare Innovation FundFrist Cressey VenturesMartin VenturesSignalFireTRANSFORMATION CAPITAL
Developing therapeutic peptides targeting rare endocrine diseases (past investment).
Co-investorsAndera PartnersATEM Capital FundCTI Life Sciences Fund L.P.EQT Life SciencesKurma PartnersOctalfa+4 more
Unable to determine company information; page contains only placeholder Lorem ipsum text.
AI & Machine LearningDigital HealthHealthtechPittsburgh, US
Gilan El Saadawi(Executive Officer, Director, Promoter)Betsy Castillo(Head of Clinical Data Abstraction)inMichael Finke(Director)Brenton Burns(Director)Scot Stevens(Director)Aaron Brauser(Executive Officer, Director, Promoter)
Co-investorsAsset Management CompanyCU Healthcare Innovation FundFrist Cressey VenturesHealthy VenturesKatalyst VenturesKatalyst.Ventures+10 more
InStride provides virtual specialty care for young people ages 7 to 24 with anxiety, OCD, and related disorders, using evidence-based treatment enhanced by AI technology.
Digital HealthHealthtechMental Health
Mona Potter(Clinical Co-founder, MD)inKathryn Boger(Clinical Co-founder, Ph.D., ABPP)inJohn Voith(Founder)in
Co-investors.406 VenturesEcho Health VenturesGeneral CatalystBlueCross BlueShield Venture Partners
.png)
Rippl delivers evidence-based dementia care through a combination of technology and human support for people living with dementia and their families.
Digital HealthHealthtechSeattle, US
Kris Engskov(Co-founder & CEO)inRobert Nelsen(Co-Founder & Board Chair)Paul Engskov(Executive Officer, Director)
BoardHolly Maloney(Director)inIyah Romm(Director)Ryan Watts(Director)
Co-investors1843 CapitalARCH Venture PartnersCity LightEquitage Ventures, L.L.C.F-Prime CapitalGeneral Catalyst+2 more
Boston-based biotech developing drugs against the 'dark genome'/repeatome for autoimmune disease, cancer and neurodegeneration.
Benjamin Greenbaum(Founder)David Ting(Founder)Rosana Kapeller(Founder)
Co-investorsAndreessen HorowitzARCH Venture PartnersGV (Google Ventures)Luma GroupSanofi VenturesAbingworth+11 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.